1. Home
  2. Analysis
  3. Inflectra
  4. Dexlansoprazole

Inflectra and Dexlansoprazole drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Inflectra (infliximab-dyyb) and Dexlansoprazole (dexlansoprazole). Common drug interactions include drug intolerance among females and disease recurrence among males.

The phase IV clinical study analyzes what interactions people have when they take Inflectra and Dexlansoprazole. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Inflectra?

Inflectra has active ingredients of infliximab-dyyb. eHealthMe is studying from 52,370 Inflectra users. Check the latest studies of Inflectra.

What is Dexlansoprazole?

Dexlansoprazole has active ingredients of dexlansoprazole. eHealthMe is studying from 3,192 Dexlansoprazole users. Check the latest studies of Dexlansoprazole.

On Jul, 16, 2026

20 people who take Inflectra and Dexlansoprazole together, and have interactions are studied.

Inflectra and Dexlansoprazole drug interactions.

What are the common drug interactions of Inflectra and Dexlansoprazole, by gender? *:

female:

  1. Drug intolerance (drug sensitivity)
  2. Chronic kidney disease
  3. Drug specific antibody present
  4. Back pain
  5. Arthroscopic surgery
  6. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  7. Chest pain
  8. Cough
  9. Dizziness
  10. Dyspnoea (difficult or laboured respiration)

male:

  1. Disease recurrence

What are the common drug interactions of Inflectra and Dexlansoprazole, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Disease recurrence

40-49:

n/a

50-59:

  1. Drug intolerance (drug sensitivity)
  2. Drug ineffective
  3. Drug specific antibody present
  4. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  5. Asthma
  6. Depression
  7. Endometriosis (appearance of endometrial tissue outside the uterus and causing pelvic pain)
  8. Hypertension (high blood pressure)
  9. Migraine (headache)
  10. Psoriasis (immune-mediated disease that affects the skin)

60+:

n/a

What are the existing conditions these people have? *

  1. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 13 people, 65.00%
  2. Migraine (headache): 8 people, 40.00%
  3. Sedation: 4 people, 20.00%
  4. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 3 people, 15.00%
  5. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 2 people, 10.00%
  6. Arthropathy: 2 people, 10.00%
  7. Dry Eyes (lack of adequate tears): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Inflectra and Dexlansoprazole?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Inflectra and Dexlansoprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Inflectra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Dexlansoprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Inflectra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dexlansoprazole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on infliximab-dyyb and dexlansoprazole (the active ingredients of Inflectra and Dexlansoprazole, respectively), and Inflectra and Dexlansoprazole (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.